12:00 AM
Aug 01, 2011
 |  BC Week In Review  |  Clinical News  |  Regulatory

CancerTYPE ID test regulatory update

bioMerieux's bioTheranostics Inc. subsidiary said that an administrator for Medicare Part B issued a positive coverage determination to...

Read the full 70 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >